Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Metastasis and AKT activation

(2011) Meng Qiao et al.   CELL CYCLE

Metastasis suppressor function of NM23-H1 requires its 3′-5′ exonuclease activity

(2010) Qingbei Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting

(2010) F. Zhu et al.   Current Molecular Pharmacology

Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity

(2009) C H Switzer et al.   ONCOGENE

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Protein phosphatase 2A regulatory subunits and cancer

(2008) Pieter J.A. Eichhorn et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

(2008) Danilo Perrotti et al.   CANCER AND METASTASIS REVIEWS

A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins

(2008) Hugh K. Arnold et al.   CANCER AND METASTASIS REVIEWS

How tumours escape mass destruction

(2008) T J Stewart et al.   ONCOGENE

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE